Condition

Head and Neck Squamous Cell Carcinoma

ClinicalTrials.gov condition label

Clinical trials125

Recruiting35

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

A Study of IDP-001 in Advanced or Metastatic Solid TumorsNCT07602842 · 2026-07-08

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsNCT07589205 · 2026-03-31

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808 · 2026-02-24

First in Human Study of SIM0610 in Solid TumorsNCT07348211 · 2026-01-19

A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNCT07274852 · 2025-12-10

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105 · 2025-11-04

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsNCT04119024 · 2025-10-07

Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer PatientsNCT07514754 · 2025-10-03

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsNCT07109726 · 2025-09-23

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · 2025-07-29

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid TumorsNCT06700070 · 2025-03-27

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationNCT06778863 · 2025-02-28

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsNCT06747585 · 2024-12-16

PET-imaging of Two Vartumabs in Patients With Solid TumorsNCT06645808 · 2024-12-10

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced CancersNCT06422403 · 2024-11-25

Thermotherapy in Addition to SOC Palliative RadiotherapyNCT06659146 · 2024-10-14

GALENOS 1 in Head and Neck, Lung, and Rectal Cancer PatientsNCT07511413 · 2024-09-23

A Study of VET3-TGI in Patients With Solid TumorsNCT06444815 · 2024-09-16

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic TherapyNCT06494995 · 2024-07-03

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069 · 2024-07-01

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid TumorsNCT06451497 · 2024-05-22

A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664 · 2024-03-19

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNCT06047379 · 2023-11-01

A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerNCT05902988 · 2023-10-18

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029 · 2023-10-13

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsNCT05983432 · 2023-08-08

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationNCT05877599 · 2023-07-12

Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCNCT05941338 · 2023-03-01

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403 · 2021-11-01

A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674 · 2021-09-29

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsNCT03740256 · 2020-12-14

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsNCT04429542 · 2020-06-01

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaNCT03556228 · 2018-06-08

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642 · 2026-10-30

NOT_YET_RECRUITING

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerNCT07667400 · 2026-10-12

NOT_YET_RECRUITING

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsNCT07807956 · 2026-09-01

NOT_YET_RECRUITING

A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723 · 2026-09-01

NOT_YET_RECRUITING

First in Human Study of QLS5316 in Solid TumorsNCT07358884 · 2026-01-01

NOT_YET_RECRUITING

Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASNCT05879484 · 2025-07-09

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid TumorsNCT07036185 · 2025-06-24

NOT_YET_RECRUITING

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersNCT06870487 · 2025-05-08

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursNCT06147037 · 2024-07-31

ACTIVE_NOT_RECRUITING

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid TumorsNCT06273852 · 2024-04-29

Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant TumorsNCT06690216 · 2024-03-30

ENROLLING_BY_INVITATION

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479 · 2024-03-05

ACTIVE_NOT_RECRUITING

Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and LungNCT05412875 · 2024-01-01

Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsNCT05858736 · 2023-07-11

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13

89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsNCT05563272 · 2023-06-06

A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsNCT05867303 · 2023-06-05

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursNCT05714553 · 2023-03-08

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant NeoplasmsNCT06307093 · 2023-03-01

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsNCT05576077 · 2023-01-17

A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsNCT05538572 · 2022-12-27

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034 · 2022-12-14

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasNCT05565417 · 2022-11-28

ACTIVE_NOT_RECRUITING

ITIL-168 in Advanced Solid TumorsNCT05393635 · 2022-08-01

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable DiseaseNCT05229614 · 2022-07-26

Common interventions

Leading sponsors

National Cancer Institute (NCI)4 AbbVie3 AstraZeneca3 Eli Lilly and Company3 Seagen Inc.3 Fate Therapeutics2 Fondazione del Piemonte per l'Oncologia2 Jacobio Pharmaceuticals Co., Ltd.2 OncoNano Medicine, Inc.2 Pure Biologics S.A.2 UNICANCER2 University of Southern California2 Alentis Therapeutics AG1 Allist Pharmaceuticals, Inc.1 Anusha Kalbasi1

Trial status mix

RECRUITING35

COMPLETED32

TERMINATED21

ACTIVE_NOT_RECRUITING19

NOT_YET_RECRUITING6

UNKNOWN6

WITHDRAWN5

ENROLLING_BY_INVITATION1

Phase mix

PHASE193

PHASE253

NA6

EARLY_PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.